Charles Schwab’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-45,182
| Closed | -$181K | – | 3500 |
|
|
2025
Q2 | $181K | Sell |
45,182
-77,108
| -63% | -$191K | ﹤0.01% | 3382 |
|
|
2025
Q1 | $111K | Sell |
122,290
-20,868
| -15% | -$28.9K | ﹤0.01% | 3330 |
|
|
2024
Q4 | $397K | Hold |
143,158
| – | – | ﹤0.01% | 3207 |
|
|
2024
Q3 | $749K | Hold |
143,158
| – | – | ﹤0.01% | 3012 |
|
|
2024
Q2 | $638K | Buy |
143,158
+16,623
| +13% | +$80.6K | ﹤0.01% | 3090 |
|
|
2024
Q1 | $969K | Buy |
126,535
+4,885
| +4% | +$26.8K | ﹤0.01% | 2808 |
|
|
2023
Q4 | $518K | Buy |
121,650
+27,655
| +29% | +$98.3K | ﹤0.01% | 3066 |
|
|
2023
Q3 | $395K | Buy |
93,995
+5,738
| +7% | +$29.2K | ﹤0.01% | 3129 |
|
|
2023
Q2 | $492K | Buy |
88,257
+71,708
| +433% | +$424K | ﹤0.01% | 3064 |
|
|
2023
Q1 | $94.8K | Hold |
16,549
| – | – | ﹤0.01% | 3258 |
|
|
2022
Q4 | $17.4K | Hold |
16,549
| – | – | ﹤0.01% | 3513 |
|
|
2022
Q3 | $45K | Hold |
16,549
| – | – | ﹤0.01% | 3352 |
|
|
2022
Q2 | $79K | Sell |
16,549
-13,948
| -46% | -$60.7K | ﹤0.01% | 3310 |
|
|
2022
Q1 | $125K | Sell |
30,497
-5,930
| -16% | -$34.9K | ﹤0.01% | 3385 |
|
|
2021
Q4 | $249K | Hold |
36,427
| – | – | ﹤0.01% | 3324 |
|
|
2021
Q3 | $423K | Sell |
36,427
-25,490
| -41% | -$398K | ﹤0.01% | 3193 |
|
|
2021
Q2 | $1.06M | Buy |
61,917
+2,422
| +4% | +$42.1K | ﹤0.01% | 2907 |
|
|
2021
Q1 | $1.18M | Buy |
59,495
+10,450
| +21% | +$231K | ﹤0.01% | 2801 |
|
|
2020
Q4 | $1.01M | Buy |
49,045
+711
| +1% | +$16.9K | ﹤0.01% | 2764 |
|
|
2020
Q3 | $1.27M | Buy |
+48,334
| New | +$1.2M | ﹤0.01% | 2619 |
|
Charles Schwab's INZY Position: Q3 2025 in Review
Charles Schwab sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 45,182 shares — an estimated $181K sold.
Charles Schwab first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $1.27M in Q3 2020. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Charles Schwab reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Charles Schwab sold 45,182 Inozyme Pharma shares in Q3 2025, an estimated $181K.
- Charles Schwab first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- Charles Schwab's Inozyme Pharma position peaked at $1.27M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.